Atyr PHARMA INC (NASDAQ:ATYR) Receives Average Rating of “Buy” from Brokerages

Shares of Atyr PHARMA INC (NASDAQ:ATYR) have received an average rating of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $18.60.

ATYR has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a report on Friday, March 14th. Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Finally, Leerink Partners assumed coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective for the company.

Atyr PHARMA Stock Performance

Shares of ATYR opened at $3.29 on Friday. Atyr PHARMA has a 1 year low of $1.42 and a 1 year high of $4.66. The company’s 50 day simple moving average is $3.27 and its 200 day simple moving average is $3.40. The company has a market capitalization of $292.82 million, a price-to-earnings ratio of -3.50 and a beta of 0.79. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.02. On average, sell-side analysts predict that Atyr PHARMA will post -0.91 EPS for the current year.

Institutional Investors Weigh In On Atyr PHARMA

A number of large investors have recently modified their holdings of ATYR. JPMorgan Chase & Co. boosted its holdings in Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock worth $55,000 after acquiring an additional 10,754 shares during the period. Kingswood Wealth Advisors LLC acquired a new stake in Atyr PHARMA during the 4th quarter valued at $170,000. Alterna Wealth Management Inc. purchased a new stake in Atyr PHARMA during the 4th quarter worth $36,000. D.A. Davidson & CO. acquired a new position in Atyr PHARMA in the 4th quarter worth $141,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Atyr PHARMA in the 4th quarter valued at about $144,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.